Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial.